NEWS

Taiwan's new drug research and development is accelerating! Anlixirong won the "2024 Moderna Taiwan mRNA Foresight Innovation Award", breaking through the bottleneck of cancer treatment, and vitiligo immune drug entered the second phase of clinical trials

Elixiron Immunotherapeutics to Initiate Phase 2 Clinical Trial of Innovative Alzheimer's Drug EI-1071 at Taipei Veterans General Hospital

EI-1071, Elixiron's drug candidate targeting microglia-induced inflammation for treating Alzheimer's disease has received the approval for a clinical trial in Taiwan

EI-001, Elixiron's drug candidate for treating vitiligo, has received approval for a clinical trial in China from the National Medical Products Administration

Elixiron partners with Yang-Ming University to jointly develop new immunotherapy technology for head and neck cancer - novel drug combining tumor macrophage-targeting antibody with interleukin-10 fusion protein

A new mechanism of IFN-γ in the pathogenesis of vitiligo reveald by a discovery from the collaborative research of Chang-Gung University and Elixiron

Elixiron Biotherapeutics Secures 2022 Part the Cloud Grant to Advance EI-1071 into Phase II Trials

Elixiron Immunotherapeutics Announces Orphan Drug Designation Granted to Interferon-Gamma-Neutralizing Antibody, EI 001 for the Treatment of Hemophagocytic Lymphohistiocytosis

Elixiron Immunotherapeutics Announces Orphan Drug Designation Granted to CSF-1R Inhibitor, EI-1071 for the Treatment of Idiopathic Pulmonary Fibrosis